Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm.

Economides MP, McCue D, Lane AA, Pemmaraju N.

Expert Rev Clin Pharmacol. 2019 Aug 29. doi: 10.1080/17512433.2019.1662297. [Epub ahead of print]

PMID:
31465247
2.

DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance.

Togami K, Pastika T, Stephansky J, Ghandi M, Christie AL, Jones KL, Johnson CA, Lindsay RW, Brooks CL, Letai A, Craig JW, Pozdnyakova O, Weinstock DM, Montero J, Aster JC, Johannessen CM, Lane AA.

J Clin Invest. 2019 Aug 22. pii: 128571. doi: 10.1172/JCI128571. [Epub ahead of print]

3.

Blastic Plasmacytoid Dendritic Cell Neoplasm-Current Insights.

Venugopal S, Zhou S, El Jamal SM, Lane AA, Mascarenhas J.

Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):545-554. doi: 10.1016/j.clml.2019.06.002. Epub 2019 Jun 13. Review.

PMID:
31281107
4.

Blastic Plasmacytoid Dendritic Cell Neoplasm: First Case Report From Rwanda and Review of the Literature.

Ruhangaza D, Mugabe MC, Kigonya CN, Lane AA, Morgan EA.

J Glob Oncol. 2019 Jun;5:1-6. doi: 10.1200/JGO.19.00123. No abstract available.

5.

Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark.

Taylor J, Haddadin M, Upadhyay VA, Grussie E, Mehta-Shah N, Brunner AM, Louissaint A Jr, Lovitch SB, Dogan A, Fathi AT, Stone RM, Tallman MS, Rampal RK, Neuberg DS, Stevenson KE, Horwitz SM, Lane AA.

Blood. 2019 Aug 22;134(8):678-687. doi: 10.1182/blood.2019001144. Epub 2019 Jun 26.

PMID:
31243042
6.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Ghandi M, Huang FW, Jané-Valbuena J, Kryukov GV, Lo CC, McDonald ER 3rd, Barretina J, Gelfand ET, Bielski CM, Li H, Hu K, Andreev-Drakhlin AY, Kim J, Hess JM, Haas BJ, Aguet F, Weir BA, Rothberg MV, Paolella BR, Lawrence MS, Akbani R, Lu Y, Tiv HL, Gokhale PC, de Weck A, Mansour AA, Oh C, Shih J, Hadi K, Rosen Y, Bistline J, Venkatesan K, Reddy A, Sonkin D, Liu M, Lehar J, Korn JM, Porter DA, Jones MD, Golji J, Caponigro G, Taylor JE, Dunning CM, Creech AL, Warren AC, McFarland JM, Zamanighomi M, Kauffmann A, Stransky N, Imielinski M, Maruvka YE, Cherniack AD, Tsherniak A, Vazquez F, Jaffe JD, Lane AA, Weinstock DM, Johannessen CM, Morrissey MP, Stegmeier F, Schlegel R, Hahn WC, Getz G, Mills GB, Boehm JS, Golub TR, Garraway LA, Sellers WR.

Nature. 2019 May;569(7757):503-508. doi: 10.1038/s41586-019-1186-3. Epub 2019 May 8.

PMID:
31068700
7.

Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy.

Mugoni V, Panella R, Cheloni G, Chen M, Pozdnyakova O, Stroopinsky D, Guarnerio J, Monteleone E, Lee JD, Mendez L, Menon AV, Aster JC, Lane AA, Stone RM, Galinsky I, Zamora JC, Lo-Coco F, Bhasin MK, Avigan D, Longo L, Clohessy JG, Pandolfi PP.

Cell Res. 2019 Jun;29(6):446-459. doi: 10.1038/s41422-019-0162-7. Epub 2019 Apr 25.

PMID:
31024166
8.

Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.

Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M.

N Engl J Med. 2019 Apr 25;380(17):1628-1637. doi: 10.1056/NEJMoa1815105.

PMID:
31018069
9.

Household composition and the infant fecal microbiome: The INSPIRE study.

Lane AA, McGuire MK, McGuire MA, Williams JE, Lackey KA, Hagen EH, Kaul A, Gindola D, Gebeyehu D, Flores KE, Foster JA, Sellen DW, Kamau-Mbuthia EW, Kamundia EW, Mbugua S, Moore SE, Prentice AM, Kvist LJ, Otoo GE, Rodríguez JM, Ruiz L, Pareja RG, Bode L, Price WJ, Meehan CL.

Am J Phys Anthropol. 2019 Jul;169(3):526-539. doi: 10.1002/ajpa.23843. Epub 2019 Apr 22.

PMID:
31012086
10.

Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity.

van Galen P, Hovestadt V, Wadsworth Ii MH, Hughes TK, Griffin GK, Battaglia S, Verga JA, Stephansky J, Pastika TJ, Lombardi Story J, Pinkus GS, Pozdnyakova O, Galinsky I, Stone RM, Graubert TA, Shalek AK, Aster JC, Lane AA, Bernstein BE.

Cell. 2019 Mar 7;176(6):1265-1281.e24. doi: 10.1016/j.cell.2019.01.031. Epub 2019 Feb 28.

PMID:
30827681
11.

More on Blastic Plasmacytoid Dendritic-Cell Neoplasms.

Pemmaraju N, Konopleva M, Lane AA.

N Engl J Med. 2019 Feb 14;380(7):695-6. doi: 10.1056/NEJMc1814963. No abstract available.

PMID:
30785714
12.

Trisomy of a Down Syndrome Critical Region Globally Amplifies Transcription via HMGN1 Overexpression.

Mowery CT, Reyes JM, Cabal-Hierro L, Higby KJ, Karlin KL, Wang JH, Kimmerling RJ, Cejas P, Lim K, Li H, Furusawa T, Long HW, Pellman D, Chapuy B, Bustin M, Manalis SR, Westbrook TF, Lin CY, Lane AA.

Cell Rep. 2018 Nov 13;25(7):1898-1911.e5. doi: 10.1016/j.celrep.2018.10.061.

13.

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN-Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community.

Pemmaraju N, Utengen A, Gupta V, Thompson MA, Lane AA.

Curr Hematol Malig Rep. 2018 Dec;13(6):581-587. doi: 10.1007/s11899-018-0490-6. Review.

PMID:
30338458
14.

Maternal iAMP21 acute lymphoblastic leukemia detected on prenatal cell-free DNA genetic screening.

Luskin MR, Discenza MN, Easter SR, Dal Cin P, Owen R, Ilagan B, Masiello M, Lane AA.

Blood Adv. 2017 Aug 15;1(19):1491-1494. doi: 10.1182/bloodadvances.2017008680. eCollection 2017 Aug 22.

15.

Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN.

Pemmaraju N, Utengen A, Gupta V, Thompson MA, Lane AA.

Curr Hematol Malig Rep. 2017 Dec;12(6):592-597. doi: 10.1007/s11899-017-0422-x. Review.

PMID:
29064025
16.

Monogenic Hashimoto thyroiditis associated with a variant in the thyroglobulin (TG) gene.

Lo MS, Towne M, VanNoy GE, Brownstein CA, Lane AA, Chatila TA, Agrawal PB.

J Autoimmun. 2018 Jan;86:116-119. doi: 10.1016/j.jaut.2017.09.003. Epub 2017 Sep 21.

PMID:
28942902
17.

Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors.

Villani AC, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J, Griesbeck M, Butler A, Zheng S, Lazo S, Jardine L, Dixon D, Stephenson E, Nilsson E, Grundberg I, McDonald D, Filby A, Li W, De Jager PL, Rozenblatt-Rosen O, Lane AA, Haniffa M, Regev A, Hacohen N.

Science. 2017 Apr 21;356(6335). pii: eaah4573. doi: 10.1126/science.aah4573.

18.

Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.

Montero J, Stephansky J, Cai T, Griffin GK, Cabal-Hierro L, Togami K, Hogdal LJ, Galinsky I, Morgan EA, Aster JC, Davids MS, LeBoeuf NR, Stone RM, Konopleva M, Pemmaraju N, Letai A, Lane AA.

Cancer Discov. 2017 Feb;7(2):156-164. doi: 10.1158/2159-8290.CD-16-0999. Epub 2016 Dec 16.

19.

Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias.

Dunford A, Weinstock DM, Savova V, Schumacher SE, Cleary JP, Yoda A, Sullivan TJ, Hess JM, Gimelbrant AA, Beroukhim R, Lawrence MS, Getz G, Lane AA.

Nat Genet. 2017 Jan;49(1):10-16. doi: 10.1038/ng.3726. Epub 2016 Nov 21.

20.

Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).

Pemmaraju N, Gupta V, Thompson MA, Lane AA.

Curr Hematol Malig Rep. 2016 Dec;11(6):462-467. doi: 10.1007/s11899-016-0340-3. Review.

PMID:
27492117
21.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM.

Cancer Cell. 2016 Jul 11;30(1):183. doi: 10.1016/j.ccell.2016.06.008. Epub 2016 Jul 11. No abstract available.

22.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM.

Cancer Cell. 2016 Apr 11;29(4):574-586. doi: 10.1016/j.ccell.2016.03.008. Erratum in: Cancer Cell. 2016 Jul 11;30(1):183.

23.

A general methodology for collecting and preserving xystodesmid and other large millipedes for biodiversity research.

Means JC, Francis EA, Lane AA, Marek PE.

Biodivers Data J. 2015 Aug 17;(3):e5665. doi: 10.3897/BDJ.3.e5665. eCollection 2015.

24.

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.

Wu SC, Li LS, Kopp N, Montero J, Chapuy B, Yoda A, Christie AL, Liu H, Christodoulou A, van Bodegom D, van der Zwet J, Layer JV, Tivey T, Lane AA, Ryan JA, Ng SY, DeAngelo DJ, Stone RM, Steensma D, Wadleigh M, Harris M, Mandon E, Ebel N, Andraos R, Romanet V, Dölemeyer A, Sterker D, Zender M, Rodig SJ, Murakami M, Hofmann F, Kuo F, Eck MJ, Silverman LB, Sallan SE, Letai A, Baffert F, Vangrevelinghe E, Radimerski T, Gaul C, Weinstock DM.

Cancer Cell. 2015 Jul 13;28(1):29-41. doi: 10.1016/j.ccell.2015.06.005.

25.

Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.

Chen YB, Lane AA, Logan B, Zhu X, Akpek G, Aljurf M, Artz A, Bredeson CN, Cooke KR, Ho VT, Lazarus HM, Olsson R, Saber W, McCarthy P, Pasquini MC.

Biol Blood Marrow Transplant. 2015 Jun;21(6):1046-1053. doi: 10.1016/j.bbmt.2015.02.005. Epub 2015 Feb 14.

26.

Mutations in G protein β subunits promote transformation and kinase inhibitor resistance.

Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu SC, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, Gritsman K, Gotlib J, Deininger MW, Makishima H, Turley SJ, Javidi-Sharifi N, Maciejewski JP, Jaiswal S, Ebert BL, Rodig SJ, Tyner JW, Marto JA, Weinstock DM, Lane AA.

Nat Med. 2015 Jan;21(1):71-5. doi: 10.1038/nm.3751. Epub 2014 Dec 8.

27.

Transmembrane Inhibitor of RICTOR/mTORC2 in Hematopoietic Progenitors.

Lee D, Sykes SM, Kalaitzidis D, Lane AA, Kfoury Y, Raaijmakers MH, Wang YH, Armstrong SA, Scadden DT.

Stem Cell Reports. 2014 Nov 11;3(5):832-40. doi: 10.1016/j.stemcr.2014.08.011. Epub 2014 Sep 25.

28.

Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.

Chen YB, Li S, Lane AA, Connolly C, Del Rio C, Valles B, Curtis M, Ballen K, Cutler C, Dey BR, El-Jawahri A, Fathi AT, Ho VT, Joyce A, McAfee S, Rudek M, Rajkhowa T, Verselis S, Antin JH, Spitzer TR, Levis M, Soiffer R.

Biol Blood Marrow Transplant. 2014 Dec;20(12):2042-8. doi: 10.1016/j.bbmt.2014.09.007. Epub 2014 Sep 17.

29.

Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation.

Lane AA, Chapuy B, Lin CY, Tivey T, Li H, Townsend EC, van Bodegom D, Day TA, Wu SC, Liu H, Yoda A, Alexe G, Schinzel AC, Sullivan TJ, Malinge S, Taylor JE, Stegmaier K, Jaffe JD, Bustin M, te Kronnie G, Izraeli S, Harris MH, Stevenson KE, Neuberg D, Silverman LB, Sallan SE, Bradner JE, Hahn WC, Crispino JD, Pellman D, Weinstock DM.

Nat Genet. 2014 Jun;46(6):618-23. doi: 10.1038/ng.2949. Epub 2014 Apr 20.

30.

A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.

Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, Kim S, van Bodegom D, Bolla S, Schatz JH, Teruya-Feldstein J, Hochberg E, Louissaint A, Dorfman D, Stevenson K, Rodig SJ, Piccaluga PP, Jacobsen E, Pileri SA, Harris NL, Ferrero S, Inghirami G, Horwitz SM, Weinstock DM.

Blood. 2014 Feb 27;123(9):1293-6. doi: 10.1182/blood-2013-10-531509. Epub 2013 Dec 17.

31.

Putative RNA-splicing gene LUC7L2 on 7q34 represents a candidate gene in pathogenesis of myeloid malignancies.

Singh H, Lane AA, Correll M, Przychodzen B, Sykes DB, Stone RM, Ballen KK, Amrein PC, Maciejewski J, Attar EC.

Blood Cancer J. 2013 May 24;3:e117. doi: 10.1038/bcj.2013.16. No abstract available.

32.

Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia.

Lane AA, Odejide O, Kopp N, Kim S, Yoda A, Erlich R, Wagle N, Abel GA, Rodig SJ, Antin JH, Weinstock DM.

Leukemia. 2013 Apr;27(4):968-71. doi: 10.1038/leu.2013.30. Epub 2013 Feb 1. No abstract available.

33.

Next-generation cDNA screening for oncogene and resistance phenotypes.

Shindoh N, Yoda A, Yoda Y, Sullivan TJ, Weigert O, Lane AA, Kopp N, Bird L, Rodig SJ, Fox EA, Weinstock DM.

PLoS One. 2012;7(11):e49201. doi: 10.1371/journal.pone.0049201. Epub 2012 Nov 7.

34.

Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation.

Weigert O, Kopp N, Lane AA, Yoda A, Dahlberg SE, Neuberg D, Bahar AY, Chapuy B, Kutok JL, Longtine JA, Kuo FC, Haley T, Salois M, Sullivan TJ, Fisher DC, Fox EA, Rodig SJ, Antin JH, Weinstock DM.

Cancer Discov. 2012 Jan;2(1):47-55. doi: 10.1158/2159-8290.CD-11-0208. Epub 2011 Dec 12.

35.

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.

Weigert O, Lane AA, Bird L, Kopp N, Chapuy B, van Bodegom D, Toms AV, Marubayashi S, Christie AL, McKeown M, Paranal RM, Bradner JE, Yoda A, Gaul C, Vangrevelinghe E, Romanet V, Murakami M, Tiedt R, Ebel N, Evrot E, De Pover A, Régnier CH, Erdmann D, Hofmann F, Eck MJ, Sallan SE, Levine RL, Kung AL, Baffert F, Radimerski T, Weinstock DM.

J Exp Med. 2012 Feb 13;209(2):259-73. doi: 10.1084/jem.20111694. Epub 2012 Jan 23.

36.

Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant.

Lane AA, Armand P, Feng Y, Neuberg DS, Abramson JS, Brown JR, Fisher DC, LaCasce AS, Jacobsen ED, McAfee SL, Spitzer TR, Freedman AS, Chen YB.

Leuk Lymphoma. 2012 Jun;53(6):1130-6. doi: 10.3109/10428194.2011.645208. Epub 2012 Jan 3.

37.

High-dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin lymphoma.

Lane AA, McAfee SL, Kennedy J, Dube C, Attar EC, Ballen KK, Dey BR, Spitzer TR, Chen YB.

Leuk Lymphoma. 2011 Jul;52(7):1363-6. doi: 10.3109/10428194.2011.572324. Epub 2011 May 25. No abstract available.

38.

Stem cells and DNA damage: persist or perish?

Lane AA, Scadden DT.

Cell. 2010 Aug 6;142(3):360-2. doi: 10.1016/j.cell.2010.07.030.

39.

A protease-resistant PML-RAR{alpha} has increased leukemogenic potential in a murine model of acute promyelocytic leukemia.

Uy GL, Lane AA, Welch JS, Grieselhuber NR, Payton JE, Ley TJ.

Blood. 2010 Nov 4;116(18):3604-10. doi: 10.1182/blood-2008-11-189282. Epub 2010 Jul 20.

40.

von Willebrand disease type 2N: uncovering a congenital bleeding disorder in a patient with hepatitis C, cirrhosis, and coagulopathy.

Lane AA, Van Cott EM, Dey BR.

Am J Hematol. 2010 Feb;85(2):134-5. doi: 10.1002/ajh.21590. No abstract available.

41.

Histone deacetylase inhibitors in cancer therapy.

Lane AA, Chabner BA.

J Clin Oncol. 2009 Nov 10;27(32):5459-68. doi: 10.1200/JCO.2009.22.1291. Epub 2009 Oct 13. Review.

PMID:
19826124
42.

Murine acute promyelocytic leukemia cells can be recognized and cleared in vivo by adaptive immune mechanisms.

Pollock JL, Lane AA, Schrimpf K, Ley TJ.

Haematologica. 2005 Aug;90(8):1042-9.

43.
44.

Expression profiling of murine acute promyelocytic leukemia cells reveals multiple model-dependent progression signatures.

Walter MJ, Park JS, Lau SK, Li X, Lane AA, Nagarajan R, Shannon WD, Ley TJ.

Mol Cell Biol. 2004 Dec;24(24):10882-93.

46.

High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression.

Westervelt P, Lane AA, Pollock JL, Oldfather K, Holt MS, Zimonjic DB, Popescu NC, DiPersio JF, Ley TJ.

Blood. 2003 Sep 1;102(5):1857-65. Epub 2003 May 15.

47.

Mouse models of acute promyelocytic leukemia.

Pollock JL, Westervelt P, Walter MJ, Lane AA, Ley TJ.

Curr Opin Hematol. 2001 Jul;8(4):206-11. Review. Erratum in: Curr Opin Hematol 2002 Mar;9(2):179.

PMID:
11561157
48.

Surface densities of ephrin-B1 determine EphB1-coupled activation of cell attachment through alphavbeta3 and alpha5beta1 integrins.

Huynh-Do U, Stein E, Lane AA, Liu H, Cerretti DP, Daniel TO.

EMBO J. 1999 Apr 15;18(8):2165-73.

49.

Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses.

Stein E, Lane AA, Cerretti DP, Schoecklmann HO, Schroff AD, Van Etten RL, Daniel TO.

Genes Dev. 1998 Mar 1;12(5):667-78.

50.

Nck recruitment to Eph receptor, EphB1/ELK, couples ligand activation to c-Jun kinase.

Stein E, Huynh-Do U, Lane AA, Cerretti DP, Daniel TO.

J Biol Chem. 1998 Jan 16;273(3):1303-8.

Supplemental Content

Support Center